Belotero Filler Is a Range, Not One Product

Belotero is not one filler. It is a family of temporary hyaluronic-acid (HA) gels with different properties and intended uses. A Tokyo quote that says only “Belotero” is therefore incomplete: the exact product, treatment area, volume, sourcing and regulatory status all matter.

Which Belotero product is being offered?

Belotero gels use a manufacturing approach called Cohesive Polydensified Matrix (CPM), which creates zones of different HA density within a cohesive gel. Published work suggests that this influences how the material distributes in tissue, but “tissue integration” is not proof that Belotero is better than every other HA filler for every face or treatment area.

The following roles come from international product information and older literature; they do not establish the approved indications in Japan:

Product named on the quote	Role described internationally	Point to clarify
Soft	Fine lines and selected superficial corrections	Which line or hollow is being treated, and at what depth?
Balance (called Basic in some markets and older literature)	Moderate lines and selected superficial-to-mid-dermal corrections	Is the proposed area covered by the exact product’s Japanese labeling?
Intense	Deeper folds and greater projection; lip volume in some markets	Is this a lip or facial-fold plan, and which evidence applies to that use?
Volume	Deeper facial volume restoration, including the midface	How many millilitres are planned, and will the quote increase if more is needed?

A 2016 literature review describes the CPM technology and these differing roles. It found the strongest evidence for Balance and Intense, while calling for more research on newer products. The review reported effects around 6–12 months in much of the evidence it assessed, although findings differed by product, area and outcome. Merz funded preparation of the review, and several authors disclosed relationships with Merz and other filler manufacturers (Clinical, Cosmetic and Investigational Dermatology).

Product names and authorized uses vary by country. In the United States, the FDA expanded Belotero Balance (+) to infraorbital hollowing in September 2023. Its 144-participant study found that results may last up to 48 weeks—a maximum finding, not a guarantee (FDA). The FDA subsequently approved Belotero Volume (+) for deep midface injection in adults aged 22 or older on May 19, 2026, and Belotero Intense (+) for lip augmentation in adults over 21 on July 9, 2026 (FDA Volume record; FDA Intense record). These are US decisions; they do not establish approval in Japan.

What to verify in Japan

Do not treat “FDA approved,” “CE marked” or “used overseas” as shorthand for Japanese approval. Ask the clinic to put the following in writing:

1. The full product name, such as Soft, Balance, Intense or Volume.
2. The syringe volume and whether the formulation contains lidocaine.
3. Whether that exact product is approved in Japan and whether the proposed area is within its approved use.
4. If it is unapproved or being used outside its approved indication, how it was obtained and what approved domestic alternatives exist.
5. Which country’s instructions for use the clinic is relying on.
6. The lot number and expiry date, with the sealed package shown before treatment.

Japan’s Ministry of Health, Labour and Welfare (MHLW) warns consumers that medicines, materials and devices used in elective aesthetic care may not be approved under Japanese law. It advises patients to understand what will be used, as well as its effectiveness and safety, before proceeding (MHLW consumer guidance).

MHLW materials on informed consent and medical advertising say that when an unapproved product—or an approved product outside its authorized use—is offered in private care, patients should receive information about its status, acquisition route, domestic alternatives, overseas safety information and the limits of public adverse-effect relief schemes (MHLW).

This distinction can be easy to miss on clinic pages. One Chiyoda clinic describes its Juvéderm range as MHLW-approved but describes Belotero by reference to FDA approval (Kioicho Plaza Clinic). That wording does not show that every Belotero variant—or every proposed use—has Japanese approval. Ask specifically about the box intended for you.

Published Tokyo prices

Clinic pages accessed on September 29, 2026 showed substantial differences in volume and included services:

• ¥49,500 for 0.5 mL Soft, ¥77,000 for 1 mL Balance and ¥93,500 for 1 mL Intense at an Omotesando clinic. A needle or cannula is listed separately at ¥3,850 (clinic price list).
• ¥60,500 for 1 mL of Balance or Intense at a Tachikawa clinic. Cannula and anesthetic options are listed separately (clinic price list).
• ¥66,000 for 1 mL Soft at another Tokyo clinic (clinic price list).
• ¥88,000 for 1 mL Soft or Basic at the Chiyoda clinic, including technique, anesthesia and cannula fees. It lists a ¥5,500 fee for later reinjection of retained product (clinic price list).

These are dated examples, not a market average or endorsements. A lower syringe price may exclude consultation, anesthesia, cannula, follow-up or correction—and a 0.5 mL syringe should not be compared directly with a 1 mL syringe.

Compare the total plan, including:

• exact product and millilitres;
• tax and consultation charges;
• anesthesia, needle or cannula fees;
• follow-up and touch-up terms;
• what happens to unused product;
• urgent and out-of-hours contact arrangements;
• who pays for assessment or treatment if a complication occurs.

Duration, downtime and risk

Visible duration depends on the exact gel, treatment area, amount, tissue movement and outcome being measured. “Up to 12 months” does not mean everyone looks unchanged for a year, and loss of visible correction does not prove that all material has disappeared. For lip treatment, our lip-filler longevity guide explains the main variables.

Common short-term filler reactions include swelling, bruising, redness, tenderness and pain. Infection, nodules, delayed inflammation, asymmetry and unwanted contours can also occur. Like other facial fillers, Belotero carries a low-probability but serious risk if material enters a blood vessel. The FDA lists tissue death, visual impairment or blindness, and stroke among reported complications (FDA dermal-filler safety guidance).

Seek immediate medical attention for unusual or escalating pain, white, gray, blue or blotchy skin, vision changes, or stroke-like symptoms during or shortly after injection. Do not wait for a routine follow-up. The US Belotero Balance (+) instructions tell practitioners to stop injecting and arrange prompt care for blanching, unusual pain, vision changes or stroke signs (product instructions).

Before paying, ask who will inject, what relevant facial-anatomy and complication training they have, and what their written vascular-occlusion response plan is. A brand name cannot compensate for an unclear treatment goal, an unverified supply chain or an emergency pathway the clinic cannot explain.